Open AccessJanus Nanobullets Combine Photodynamic Therapy and Magnetic Hyperthermia to Potentiate Synergetic Anti‐Metastatic Immunotherapy
Author(s) -
Wang Zheng,
Zhang Fan,
Shao Dan,
Chang Zhimin,
Wang Lei,
Hu Hanze,
Zheng Xiao,
Li Xuezhao,
Chen Fangman,
Tu Zhaoxu,
Li Mingqiang,
Sun Wen,
Chen Li,
Dong WenFei
Publication year - 2019
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201901690
Subject(s) - hyperthermia , magnetic hyperthermia , photodynamic therapy , immunotherapy , immunogenic cell death , cancer research , photosensitizer , medicine , metastasis , combination therapy , immune checkpoint , cancer immunotherapy , immune system , magnetic nanoparticles , cancer , chemistry , materials science , immunology , nanotechnology , nanoparticle , organic chemistry
Abstract Photodynamic therapy (PDT) is clinically promising in destructing primary tumors but ineffective against distant metastases. This study reports the use of immunogenic nanoparticles mediated combination of PDT and magnetic hyperthermia to synergistically augment the anti‐metastatic efficacy of immunotherapy. Janus nanobullets integrating chlorine e6 (Ce6) loaded, disulfide‐bridged mesoporous organosilica bodies with magnetic heads (M‐MONs@Ce6) are tailored for redox/pH‐triggered photosensitizer release accompanying their matrix degradation. Cancer cell membrane cloaking enables favorable tumor‐targeted accumulation and prolonged blood circulation time of M‐MONs@Ce6. The combination of PDT and magnetic hyperthermia has a strong synergy anticancer activity and simultaneously elicits a sequence of immunogenic cell death, resulting in synergistically tumor‐specific immune responses. When combined with anti‐CTLA‐4 antibody, the biomimetic and biodegradable nanoparticle enables the notable eradication of primary and deeply metastatic tumors with low systematic toxicity, thus potentially advancing the development of combined hyperthermia, PDT, and checkpoint blockade immunotherapy to combat cancer metastasis.